Prestige Biologics

프레스티지바이오로직스(주) · KOSDAQ · 334970 · Industry: Manufacture of medicaments

Key metrics

Earnings

Revenue, Q3 2026₩2.3bn As of Sep 30, 2026 Source 1 ↗
Revenue QoQNot available
Revenue YoY-34.8% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Operating income, Q3 2026-₩16.3bn As of Sep 30, 2026 Source 1 ↗
Operating income QoQNot available
Operating income YoY-124.5% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗

Share buybacks

Buyback decided, last 3 months₩0 As of Nov 19, 2026
Buyback decided, last 3 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Shares acquired, last 3 months₩0 As of Nov 19, 2026
Shares acquired, last 3 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Treasury shares cancelled, last 3 months₩0 As of Nov 19, 2026
Treasury shares cancelled (number), last 3 months0 shares As of Nov 19, 2026
Treasury shares cancelled, last 3 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Buyback decided, last 12 months₩0 As of Nov 19, 2026
Buyback decided, last 12 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Shares acquired, last 12 months₩0 As of Nov 19, 2026
Shares acquired, last 12 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Treasury shares cancelled, last 12 months₩0 As of Nov 19, 2026
Treasury shares cancelled (number), last 12 months0 shares As of Nov 19, 2026
Treasury shares cancelled, last 12 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗

Potential dilution

CB/BW/EB issued, last 12 months₩0 As of Nov 19, 2026
Rights offering new shares, last 12 months0 shares As of Nov 19, 2026
Potential new shares, last 12 months5,516,340 shares As of Jun 22, 2026 Source 1 ↗, Source 2 ↗
Potential new shares, % of shares7.1% As of Jun 22, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗
Conversion price adjustments, last 12 months2 As of Jun 22, 2026 Source 1 ↗, Source 2 ↗

Supply contracts

Supply contracts, last 12 months₩39.2bn As of Nov 12, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗, Source 4 ↗, Source 5 ↗ +1 more
Supply contracts vs prior-year revenue312.7% As of Nov 12, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗, Source 4 ↗, Source 5 ↗ +1 more
Contracts without a KRW amount0 contracts without a KRW amount excluded As of Nov 19, 2026

Disclosure activity

DART filings, last 3 months15 As of Nov 19, 2026
DART filings, previous 3 months9 As of Nov 19, 2026

Insider transactions

Open-market buys, last 12 months (shares)186,100 shares As of Nov 9, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗
Open-market buys, last 12 months (amount)₩289m As of Nov 9, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗
Open-market sells, last 12 months (shares)0 shares As of Nov 19, 2026
Open-market sells, last 12 months (amount)₩0 As of Nov 19, 2026
Net open-market buying, last 12 months (shares)186,100 shares As of Nov 9, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗
Insiders who bought, last 12 months2 As of Nov 9, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗

Insider transactions (last 12 months)

Open-market buys: 186,100 shares (₩289m). Open-market sells: 0 shares (₩0). Net open-market buying: +186,100 shares. Insiders who bought: 2.

Trade dateInsider (role)TypeSharesPriceAmount
Nov 9, 2026Lim Yeong-su (Registered director)Open-market buy+11,500 shares₩1,161₩13m
Nov 6, 2026Lim Yeong-su (Registered director)Open-market buy+3,000 shares₩1,168₩4m
Nov 5, 2026Lim Yeong-su (Registered director)Open-market buy+39,000 shares₩1,150₩45m
Nov 5, 2026Lim Yeong-su (Registered director)Other (OTC buy)+55,000 shares₩1,179₩65m
Nov 4, 2026Lim Yeong-su (Registered director)Open-market buy+29,000 shares₩1,131₩33m
Jul 9, 2026Kim Jin-u (Registered director, 10%+ shareholder)Open-market buy+3,600 shares₩1,985₩7m
Jun 30, 2026Kim Jin-u (Registered director, 10%+ shareholder)Open-market buy+8,000 shares₩1,946₩16m
Jun 29, 2026Kim Jin-u (Registered director, 10%+ shareholder)Open-market buy+16,213 shares₩1,942₩31m
Jun 26, 2026Kim Jin-u (Registered director, 10%+ shareholder)Open-market buy+28,787 shares₩1,866₩54m
Jun 25, 2026Kim Jin-u (Registered director, 10%+ shareholder)Open-market buy+22,000 shares₩1,868₩41m
Jun 24, 2026Kim Jin-u (Registered director, 10%+ shareholder)Open-market buy+25,000 shares₩1,814₩45m

Annual financials

YearRevenueOperating income
2025₩12.5bn-₩33.7bn
2024₩2.2bn-₩33.4bn
2023₩1.7bn-₩22.1bn

Filing timeline